Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MWN109 Injection in Healthy and Overweight/Obese Subjects
NCT06859853Phase 1Recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing MWN109 Injection with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events at Day 50, Change in Laboratory Parameters at Day 50 and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
MWN109
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06859853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859853.